Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in Patients with Advanced Hepatocellular Carcinoma
- 30 July 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4292-4306
Abstract
Purpose: Treatment options for advanced hepatocellular carcinoma (HCC) remain limited, and responses to later-line therapies are modest. Glypican 3 (GPC3), highly expressed in HCC but rarely in normal tissues, is an attractive tumor-specific target. CT0180 is a GPC3-targeted single-chain fragment variable linked to CD3ε designed to integrate into the native T-cell receptor (TCR) complex and activate full TCR signaling upon GPC3 binding. Patients and Methods: In this open-label, dose-escalation phase I trial, patients with advanced GPC3-positive HCC that had progressed on or were intolerant to standard therapies received CT0180 after fludarabine/cyclophosphamide lymphodepletion. The study objectives were safety, preliminary efficacy, and cellular pharmacokinetics. Single-cell RNA sequencing (scRNA-seq) and TCR sequencing were used to profile immune reconstitution. Results: Seven patients received 15 infusions across 4 dose levels (DL): 1 × 107 (n = 1), 3 × 107 (n = 1), 1 × 108 (n = 3), and 3 × 108 (n = 2) cells. Grade 3 to 4 adverse events were primarily hematologic. Cytokine release syndrome occurred in 85.7% of patients, all grade 1 with no dose-limiting toxicities or immune effector cell–associated neurotoxicity observed. Two patients (at DL2 and DL4) achieved partial responses, and 3 (at DL1, DL3, and DL4) achieved stable disease, yielding an objective response rate of 28.6% and a disease control rate of 71.4%. The median progression-free survival and overall survival were 7.6 and 11.6 months, respectively. scRNA-seq revealed baseline NK-cell enrichment in patients with clinical benefit and sustained cytotoxic CD8 effector expansion after repeat infusion. Conclusions: CT0180 demonstrated a preliminary manageable safety profile and clinical activity in heavily pretreated HCC, supporting further clinical evaluation.Keywords
All Related Versions
Funding Information
- The National Natural Science Foundation of China (82188102)
- The National Natural Science Foundation of China (82202875)
This publication has 40 references indexed in Scilit:
- Natural killer cell therapy in hepatocellular carcinoma: a comprehensive reviewDiscover Oncology, 2025
- RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trialeClinicalMedicine, 2023
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyThe Lancet, 2023
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityCancer Cell, 2022
- Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumorsMolecular Therapy-Oncolytics, 2022
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaJournal of Hepatology, 2022
- Integrated analysis of multimodal single-cell dataCell, 2021
- Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinomaJournal of Hepatology, 2020
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2019
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017